Document is current
Any future updates will be listed below
-
Authors
Watkins, Thomas B. K.
Lim, Emilia L.
Petkovic, Marina https://orcid.org/0000-0003-2875-216X
Elizalde, Sergi https://orcid.org/0000-0003-4116-2455
Birkbak, Nicolai J. https://orcid.org/0000-0003-1613-9587
Wilson, Gareth A.
Moore, David A.
Grönroos, Eva https://orcid.org/0000-0001-8303-5409
Rowan, Andrew
Dewhurst, Sally M.
Demeulemeester, Jonas https://orcid.org/0000-0002-2660-2478
Dentro, Stefan C.
Horswell, Stuart https://orcid.org/0000-0003-2787-1933
Au, Lewis
Haase, Kerstin https://orcid.org/0000-0002-0944-5618
Escudero, Mickael https://orcid.org/0000-0002-1336-815X
Rosenthal, Rachel
Bakir, Maise Al
Xu, Hang
Litchfield, Kevin
Lu, Wei Ting https://orcid.org/0000-0002-1405-4806
Mourikis, Thanos P.
Dietzen, Michelle
Spain, Lavinia
Cresswell, George D. https://orcid.org/0000-0003-3303-068X
Biswas, Dhruva https://orcid.org/0000-0001-9141-5188
Lamy, Philippe
Nordentoft, Iver
Harbst, Katja https://orcid.org/0000-0002-8225-1510
Castro-Giner, Francesc https://orcid.org/0000-0001-6111-0754
Yates, Lucy R.
Caramia, Franco https://orcid.org/0000-0002-5086-2544
Jaulin, Fanny https://orcid.org/0000-0002-5110-1800
Vicier, Cécile
Tomlinson, Ian P. M.
Brastianos, Priscilla K.
Cho, Raymond J. https://orcid.org/0000-0001-6090-6603
Bastian, Boris C. https://orcid.org/0000-0003-1836-6062
Dyrskjøt, Lars https://orcid.org/0000-0001-7061-9851
Jönsson, Göran B.
Savas, Peter https://orcid.org/0000-0001-5999-428X
Loi, Sherene https://orcid.org/0000-0001-6137-9171
Campbell, Peter J. https://orcid.org/0000-0002-3921-0510
Andre, Fabrice https://orcid.org/0000-0001-5795-8357
Luscombe, Nicholas M. https://orcid.org/0000-0001-5293-4778
Steeghs, Neeltje
Tjan-Heijnen, Vivianne C. G.
Szallasi, Zoltan
Turajlic, Samra https://orcid.org/0000-0001-8846-136X
Jamal-Hanjani, Mariam
Van Loo, Peter https://orcid.org/0000-0003-0292-1949
Bakhoum, Samuel F.
Schwarz, Roland F. https://orcid.org/0000-0001-9155-4268
McGranahan, Nicholas https://orcid.org/0000-0001-9537-4045
Swanton, Charles https://orcid.org/0000-0002-4299-3018
- License Information
-
More Information
Article History
Received: 1 April 2019
Accepted: 24 June 2020
First Online: 2 September 2020
Competing interests
: G.A.W. has consulted for and has stock options in Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca. M.A.B. has consulted for Achilles Therapeutics. C.V. has received travel expenses from Astellas, Roche and Pfizer, and grant support from Bristol Myers Squibb. R.R. has consulted for and has stock options in Achilles Therapeutics. K.L. reports speaker fees from Roche Tissue Diagnostics. P.K.B. has consulted for Angiochem, Roche-Genentech, Eli Lilly, Tesaro, ElevateBio, Pfizer (Array), and received grant or research support from Merck, Bristol Myers Squibb and Eli Lilly and honoraria from Merck, Roche-Genentech and Eli Lilly. L.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory/consulting role at Ferring. P.S. serves an uncompensated consultant for Roche-Genentech. S.L. receives research funding to her institution from Novartis, Bristol Myers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly and Seattle Genetics, has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, Bristol Myers Squibb, Merck, AstraZeneca and Roche-Genentech and has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline and G1 Therapeutics. F.A. is a member of the Advisory Boards for Pfizer, AstraZeneca, Eli Lilly, Roche-Genentech, Novartis and Daiichi Sankyo, acknowledges grant support from Pfizer, AstraZeneca, Eli Lilly, Novartis and Daiichi Sankyo and is a co-founder of Pegacsy. V.C.G.T.-H. reports grants and personal fees from Pfizer, Roche, Novartis and Eli Lilly, grants from Eisai and personal fees from Accord. S.T. has received funding from Ventana Medical Systems Inc (grant numbers 10467 and 10530), has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen and has the following European and US patent filed: Indel mutations as a therapeutic target and predictive biomarker (PCTGB2018/051892) and European patent: Clear Cell Renal Cell Carcinoma Biomarkers (P113326GB). M.J.-H. is a member of the Advisory Board for Achilles Therapeutics. S.F.B. holds a patent related to some of the work described targeting CIN and the cGAS-STING pathway in advanced cancer, owns equity in, receives compensation from and serves as a consultant and on the Scientific Advisory Board and Board of Directors of Volastra Therapeutics, and has also consulted for Sanofi, received sponsored travel from the Prostate Cancer Foundation, and both travel and compensation from Cancer Research UK. N.M. has stock options in and has consulted for Achilles Therapeutics and holds a European patent in determining HLA LOH (PCT/GB2018/052004). C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board Member and Chief Investigator for the MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options and is co-founder of Achilles Therapeutics. C.S. holds European patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892).
